清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

CRISPR-Based Therapy for Hereditary Angioedema

遗传性血管水肿 清脆的 医学 计算生物学 遗传学 生物 皮肤病科 基因
作者
Danny M. Cohn,Padmalal Gurugama,Markus Magerl,Constance H. Katelaris,D. Launay,Laurence Bouillet,Remy S. Petersen,Karen Lindsay,Emel Aygören‐Pürsün,David Maag,James S. Butler,Mrinal Y. Shah,Adele Golden,Yuanxin Xu,Ahmed M. Abdelhady,David Lebwohl,Hilary Longhurst
出处
期刊:The New England Journal of Medicine [New England Journal of Medicine]
标识
DOI:10.1056/nejmoa2405734
摘要

BackgroundHereditary angioedema is a rare genetic disease characterized by severe and unpredictable swelling attacks. NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9. NTLA-2002 targets the gene encoding kallikrein B1 (KLKB1). A single dose of NTLA-2002 may provide lifelong control of angioedema attacks.MethodsIn this phase 2 portion of a phase 1–2 trial, we randomly assigned adults with hereditary angioedema in a 2:2:1 ratio to receive NTLA-2002 in a single dose of 25 mg or 50 mg or placebo. The primary end point was the number of angioedema attacks per month (the monthly attack rate) from week 1 through week 16. Secondary end points included safety, pharmacokinetics, and pharmacodynamics (i.e., the change from baseline in total plasma kallikrein protein level); exploratory end points included patient-reported outcomes.ResultsOf the 27 patients who underwent randomization, 10 received 25 mg of NTLA-2002, 11 received 50 mg, and 6 received placebo. From week 1 through week 16, the estimated mean monthly attack rate was 0.70 (95% confidence interval [CI], 0.25 to 1.98) with 25 mg of NTLA-2002, 0.65 (95% CI, 0.24 to 1.76) with 50 mg, and 2.82 (95% CI, 0.80 to 9.89) with placebo; the difference in the estimated mean attack rate with NTLA-2002 as compared with placebo was −75% with 25 mg and −77% with 50 mg. Among patients who received NTLA-2002, 4 of the 10 patients who received 25 mg (40%) and 8 of the 11 who received 50 mg (73%) were attack-free with no additional treatment during the period from week 1 through week 16. The most common adverse events among patients who received NTLA-2002 were headache, fatigue, and nasopharyngitis. The mean percent change in total plasma kallikrein protein levels from baseline to week 16 was −55% with 25 mg and −86% with 50 mg; levels remained unchanged with placebo.ConclusionsNTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema. These results support continued investigation in a larger phase 3 trial. (Funded by Intellia Therapeutics; ClinicalTrials.gov number, NCT05120830; EudraCT number, 2021-001693-33.)
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李志全完成签到 ,获得积分10
21秒前
1分钟前
1分钟前
颖宝老公发布了新的文献求助10
1分钟前
2分钟前
iberis完成签到 ,获得积分10
3分钟前
3分钟前
悦耳绝施完成签到,获得积分10
4分钟前
茶茶完成签到,获得积分10
4分钟前
msirtx完成签到,获得积分10
4分钟前
Alan完成签到 ,获得积分10
4分钟前
Ava应助帮帮我好吗采纳,获得10
5分钟前
爱心完成签到 ,获得积分10
5分钟前
Lucas应助帮帮我好吗采纳,获得10
5分钟前
5分钟前
6分钟前
hongt05完成签到 ,获得积分10
6分钟前
6分钟前
搞怪的白云完成签到 ,获得积分10
6分钟前
忧郁静白发布了新的文献求助10
6分钟前
thangxtz完成签到,获得积分10
6分钟前
9494完成签到,获得积分10
7分钟前
忧郁静白完成签到 ,获得积分20
8分钟前
8分钟前
8分钟前
mzhang2完成签到 ,获得积分10
8分钟前
8分钟前
Emperor完成签到 ,获得积分0
8分钟前
合适的寄灵完成签到 ,获得积分10
9分钟前
朴素的山蝶完成签到 ,获得积分10
9分钟前
9分钟前
李爱国应助科研通管家采纳,获得10
9分钟前
Drwenlu完成签到,获得积分10
10分钟前
10分钟前
习月阳完成签到,获得积分10
10分钟前
领导范儿应助帮帮我好吗采纳,获得10
10分钟前
10分钟前
baobeikk完成签到,获得积分10
11分钟前
11分钟前
充电宝应助帮帮我好吗采纳,获得10
11分钟前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3137034
求助须知:如何正确求助?哪些是违规求助? 2788014
关于积分的说明 7784270
捐赠科研通 2444088
什么是DOI,文献DOI怎么找? 1299724
科研通“疑难数据库(出版商)”最低求助积分说明 625522
版权声明 600999